IW 319

November 5, 2025 Viktor Zarev 0 min read
  1. FDA rocked by latest personnel controversy as Tidmarsh resigns.
  2. FDA to discuss health risk of chatbots at advisory meeting.
  3. Trump administration nears cost deals with drug makers.
  4. Medicare cuts 2026 reimbursement rates to specialty physicians.
  5. Hippocratic AI raises $126M to build healthcare AI agents.
  6. “Free” AI pilots are costing health systems millions. 
  7. Kimberly-Clark to buy Tylenol maker despite Trump autism claims.
  8. Healthcare M&A lags 2024’s pace.
  9. Male doctors get mammograms to raise screening awareness.
  10. Maine health system apologizes to 531 (living) patients declared dead.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiovascular Disease May 11, 2026

BP Lowering Still Decreases CVD Risk Even in CKD May 11, 2026

Data from a new Lancet study suggests that patients with chronic kidney disease (CKD) might get similar cardiovascular protection from blood pressure drugs as the general population, giving physicians some certainty about how to approach BP in these patients.

Cardiology Pharmaceuticals May 7, 2026

Aficamten, ACACIA-HCM, and the Road to the First nHCM Drug May 7, 2026

The question of how to treat non-obstructive hypertrophic cardiomyopathy has long perplexed researchers and pharmaceutical developers alike, but topline results from Cytokinetics’ Phase 3 ACACIA-HCM trial suggest MYQORZO (aficamten) could be the answer.

Cardiovascular Disease May 4, 2026

The True Cause of Sudden Cardiac Death May 4, 2026

It’s not often that a pair of studies completely challenges our assumptions in cardiology, but new data presented at HRS 2026 suggests myocardial infarction might not be […]